(Microbicide Trials Network) Researchers have launched the first trial directly comparing the pill and vaginal gel formulations of the antiretroviral drug tenofovir to answer key questions about their use as HIV prevention in women.
Are there differences in how the drug is absorbed, especially in the vagina's infection-prone cells? And will women prefer one daily approach over another?
Findings will help determine optimal dosing of and adherence to ARV-based prevention methods.
Popular products
Post new comment